Cenix BioScience GmbH Follows up Successful RNAi-Based Target Discovery Screens with Target Validation Study for AstraZeneca PLC

Published: Mar 19, 2009

DRESDEN, Germany--(BUSINESS WIRE)--Cenix BioScience GmbH, a leading RNA interference (RNAi)-focused contract research organization, today announced that it has initiated a second research project under its existing framework research agreement with AstraZeneca Pharmaceuticals LP, one of the world’s leading pharmaceutical companies.

Back to news